参考文献/References:
[1] Libby P.Inflammation in atherosclerosis[J].Nature,2002,420:868-874.
[2] Kolodgie FD,Burke AP,Skorija KS,et al.Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis[J].Arterioscler Thromb Vasc Biol,2006,26:2523-2529.
[3] Tjoelker LW,Wilder C,Eberhardt C,et al.Anti-inflammatory properties of a platelet-activating factor acetylhydrolase[J].Nature,1995,374:549-553.
[4] Wilensky RL,Hamamdzic D.The molecular basis of vulnerable plaque:potential therapeutic role for immunomodulation[J].Curr Opin Cardiol,2007,22:545-551.
[5] Garza CA,Montori VM,Mcconelli JP,et al.Association between lipoprotein-associated phospholipase A2 and cardiovascular disease:a systematic review[J].Mayo Clin Proc,2007,82:159-165.
[6] Hakkien T,Luoma JS,Hiltunen MO,et al.Lipoprotein-associated phospholipase A2,platelet-activating factor acetylhydrolase,is expressed by macrophages in human and rabbit atherosclerotic lesions[J].Arterioscler Thromb Vasc Biol,1999,19:2909-2917.
[7] Thompson A,Gao P,Orfei L,et al.Lipoprotein-associated phospholipase A(2)and risk of coronary disease, stroke, and mortality:collaborative analysis of 32 prospective studies[J].Lancet,2010,375:1536-1544.
[8] Braun TL, Davidson MH.Lp-PLA2:a new target for statin therapy[J].Curr Atheroscler Rep,2010,12:29-33.
[9] White HD,Simes J,Stewart RA,et al.Changes in lipoprotein-associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-term Intervention with Pravastatin in Ischemic Disease Study[J].J Am Heart Assoc,2013 2(5):e000360.
[10] Moutzouri E,Liberopoulos EN,Tellis CC,et al.Comparison of the effect of simvastatin versus simvastatin/ezetimibe versus rosuvastatin on markers of inflammation and oxidative stress in subjects with hypercholesterolemia[J].Atherosclerosis,2013,231(1):8-14.
[11] Heart Protection Study Collaborative Group.Lipoprotein-associated phospholipase A2 activity and mass in relation to vascular disease and nonvascular mortality[J].J Intern Med,2010,268:348-358.
[12] Ridker PM,MacFadyen JG,Wolfert RL,et al.Relationship of lipoprotein associated phospholipase A(2)mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy:an analysis from the JUPITER trial[J].Clin Chem,2012,58:877-886.
[13] Ryu SK,Mallat Z,Benessiano J,et al.Phospholipase A2 enzymes,high-dose atorvastatin,and prediction of ischemic events after acute coronary syndromes[J].Circulation,2012,125(6):757-766.
[14] Le NA,Tomassini JE,Tershakovec AM,et al.Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid-Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease[J].J Am Heart Assoc,2015,4(10):e001675.
[15] Winkler K,Winkelmann BR,Scharnagl H,et al.Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors:the Ludwigshafen Risk and Cardiovascular Health Study[J].Circulation,2005,111:980-987.
[16] Banfi C,Cavalca V,Veglia F,et al.Neurohormonal activation is associated with increased levels of plasma matrix metalloproteinase-2 in human heart failure[J].Eur Heart J,2005,26:481-488.
[17] Spence JD.Effects of antihypertensive drugs on flow disturbances:nifedipine,captopril,and metoprolol evaluated by quantitative spectral analysis of Doppler flow patterns in patients with carotid stenosis[J].Clin Invest Med,1994,17:319-325.
[18] Asciutto G,Edsfeldt A,Dias NV,et al.Treatment with beta-blockers is associated with lower levels of Lp-PLA2 and suPAR in carotid plaques[J].Cardiovasc Pathol,2013,22(6):438-443.
[19] Hanss R,Bein B.Organ protection in cardiac risk patients—rational of perioperative beta-adrenoceptor-antagonists and statins[J].AINS,2010,45(4):246-252.
[20] Chonchol M,Benderly M,Goldbourt U.Beta-blockers for coronary heart disease in chronic kidney disease[J].Nephrol Dial Transplant,2008,23(7):2274-2279.
[21] Garcia-Garcia HM,Serruys PW.Phospholipase A2 inhibitors[J].Curr Opin Lipidol,2009,20:327-332.
[22] Wilensky RL,Shi Y,Mohler ER 3rd,et al.Inhibition of lipoprotein associated phospholipase A2 reduces complex coronary atherosclerotic plaque development[J].Nat Med,2008,14:1059-1066.
[23] Wilensky RL,Macphe CH.Lipoprotein-associated phospholipase A2 and atherosclerosis[J].Curr Opin Lipidol,2009,20:415-420.
[24] Daida H,Iwase T,Yagi S,et al.Effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity in Japanese dyslipidemic patients, with exploratory analysis of a PLA2G7 gene polymorphism of Val279Phe[J].Circ J,2013,77(6):1518-1525.
[25] Serruys PW,Garcia-Garcia HM,Buszman P,et al.Effects of the direct lipoprotein-associated phospholipase A(2)inhibitor darapladib on human coronary atherosclerotic plaque[J].Circulation,2008,118:1172-1182.
[26] The stability investigators,White HD,Held C,et al.Darapladib for preventing ischemic events in stable coronary heart disease[J].N Engl J Med,2014,370(18):1702-1711.
[27] O'Donoghue ML,Braunwald E,White HD,et al.Effect of darapladib on major coronary events after an acute coronary syndrome:the SOLID-TIMI 52 randomized clinical trial[J].JAMA,2014,312(10):1006-1015.
[28] Davidson MH,Corson MA,Alberts MJ,et al.Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines[J].Am J Cardiol,2008,101:51F-57F.
相似文献/References:
[1]白春兰,张军.正五聚蛋白-3:新型心血管病炎性标志物[J].心血管病学进展,2016,(1):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
BAI Chunlan,ZHANG Jun.Pentraxin-3: A Novel Inflammation Biomarker for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(2):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
[2]阎萌,田芳,综述,等.程序性坏死与动脉粥样硬化[J].心血管病学进展,2016,(2):139.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.011]
YAN Meng,TIAN Fang,TIAN Ye.Necroptosis and Atherosclerosis[J].Advances in Cardiovascular Diseases,2016,(2):139.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.011]
[3]李乐亮,综述,李萍,等.炎症标志物与颈动脉粥样斑块的稳定性[J].心血管病学进展,2016,(3):219.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.001]
LI Leliang,LI Ping.Stability of Inflammatory Markers and Carotid Artery Plaque[J].Advances in Cardiovascular Diseases,2016,(2):219.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.001]
[4]杨娟,综述,王佑华,等.肠道菌群与血管内炎症[J].心血管病学进展,2016,(3):263.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.012]
YANG Juan,WANG Youhua,YUAN Suyun.Relationship Between Gut Microbiota and Vascular Inflammation[J].Advances in Cardiovascular Diseases,2016,(2):263.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.012]
[5]夏平,杨浩.炎症与心房颤动相关性的研究进展[J].心血管病学进展,2015,(5):637.[doi:10.3969/j.issn.1004-3934.2015.05.030]
XIA Ping,YANG Hao.Research Progress of Inflammation Associated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(2):637.[doi:10.3969/j.issn.1004-3934.2015.05.030]
[6]李文松 张润峰.脂蛋白相关磷脂酶与冠心病的相关性研究进展[J].心血管病学进展,2020,(1):85.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.023]
LI Wensong ZHANG Runfeng.Lipoprotein-associated Phospholipase A2 and Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2020,(2):85.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.023]